Alginomics' anticancer drug RZ-001 receives FDA Fast Track designation for hepatocellular carcinoma treatment, marking its second such designation following glioblastoma in November 2023.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.